Key result
Anticoagulation-free ECMO is a viable option for critically ill patients with active or high risk of major bleeding, though limited data is available on its safety and efficacy.
Why the study?
Standard systemic anticoagulation is not possible in ECMO patients with active or high risk of major bleeding, but limited data exist on the safety and efficacy of anticoagulant-free ECMO protocols.
Is anticoagulant-free ECMO a viable option for patients with severe respiratory or cardiac failure who have an active or high risk of major bleeding?
Is anticoagulant-free ECMO a viable option for patients with severe respiratory or cardiac failure who have an active or high risk of major bleeding?
Anticoagulant-free ECMO may be a viable strategy for critically ill patients requiring ECMO who have an active or high risk of major bleeding, despite limited data.
Balancing thrombosis and bleeding in ECMO remains challenging; review leaves open optimal protocols and monitoring strategies.
Extracorporeal membrane oxygenation (ECMO) is an advanced life-saving therapy that has been used in recent years for the treatment of severe respiratory failure or cardiac failure.The use of extracorporeal circuit exposes blood to non-biologic, thrombogenic surfaces, and therefore, ECMO protocols recommend systemic anticoagulation for patients on ECMO.Extracorporeal membrane oxygenation is a complex procedure in which anticoagulation is given ideally to balance between prevention of thrombosis and control of bleeding.The presence of active bleeding or coagulopathy in critically ill patients makes the choice of the anticoagulation strategy very challenging.In patients with active or high risk of major bleeding, standard systemic anticoagulation is not possible and in such situation the prospect of anticoagulation-free ECMO is a viable option.Although only limited data is available on the safety and efficacy of this practice, many centers adopt low and anticoagulant-free ECMO protocols in patients with high bleeding risk.In this literature, we have discussed the clinical prospects of anticoagulation-free ECMO.
No takes yet. Share an insight, caveat, or question.
R Prasannakumar (2025) conducted a review in Severe respiratory or cardiac failure requiring ECMO with high bleeding risk. Anticoagulant-free ECMO vs. Standard systemic anticoagulation was evaluated. Anticoagulation-free ECMO is a viable option for critically ill patients with active or high risk of major bleeding, though limited data is available on its safety and efficacy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: